Page last updated: 2024-10-24

germinal center B cell differentiation

Definition

Target type: biologicalprocess

The process in which a B cell in the spleen acquires the specialized features of a germinal center B cell. Germinal center B cells are rapidly cycling B cells which have downregulated IgD expression and exhibit high levels of binding by peanut agglutinin (PNA). [GOC:jal, ISBN:0781735149]

Germinal center (GC) B cell differentiation is a critical process in adaptive immune responses, leading to the generation of high-affinity antibody-producing plasma cells and memory B cells. It occurs in specialized microenvironments within secondary lymphoid organs, primarily lymph nodes and the spleen. The process is initiated by the activation of naive B cells by antigen-presenting cells (APCs), which triggers their migration into follicles. Within the follicle, activated B cells encounter antigen-specific T follicular helper (Tfh) cells, leading to the formation of GCs. GCs are characterized by a dynamic interplay between B cells, Tfh cells, and follicular dendritic cells (FDCs).

The differentiation of B cells within GCs is a multi-step process involving:

1. **Entry into the GC:** Activated B cells enter the GC, where they undergo rapid proliferation and somatic hypermutation (SHM) of their immunoglobulin (Ig) genes. This introduces mutations in the variable regions of Ig genes, resulting in a diverse pool of B cells expressing antibodies with varying affinities for the antigen.

2. **Selection and affinity maturation:** B cells compete for limited amounts of antigen presented on FDCs. B cells that bind the antigen with higher affinity are preferentially selected for survival and further proliferation. This process, known as affinity maturation, drives the evolution of B cells with progressively higher antigen binding affinity.

3. **Differentiation into plasma cells or memory B cells:** Following several rounds of proliferation and affinity maturation, GC B cells differentiate into either plasma cells or memory B cells. Plasma cells migrate to bone marrow or other sites of antibody production and secrete high-affinity antibodies. Memory B cells are long-lived cells that can rapidly differentiate into plasma cells upon re-exposure to the antigen, providing long-term immunity.

Key factors regulating GC B cell differentiation include:

* **B cell receptor (BCR) signaling:** Engagement of the BCR by antigen triggers a signaling cascade that promotes B cell survival, proliferation, and differentiation.
* **Tfh cell interactions:** Tfh cells provide essential signals, including cytokines such as IL-21, IL-4, and IL-6, that drive B cell differentiation and antibody production.
* **FDC interactions:** FDCs provide a platform for antigen presentation and regulate B cell survival and differentiation.
* **Cytokine milieu:** The cytokine environment within the GC influences the fate of B cells, determining whether they differentiate into plasma cells or memory B cells.

GC B cell differentiation is a highly regulated process that ensures the generation of high-affinity antibody responses against specific antigens. It plays a crucial role in maintaining long-term immunity and protecting against infectious diseases.'
"

Proteins (2)

ProteinDefinitionTaxonomy
Interleukin-6An interleukin-6 that is encoded in the genome of human. [PRO:JAN, UniProtKB:P05231]Homo sapiens (human)
Adenosine deaminaseAn adenosine deaminase that is encoded in the genome of human. [PRO:DNx, UniProtKB:P00813]Homo sapiens (human)

Compounds (12)

CompoundDefinitionClassesRoles
9-(2-hydroxy-3-nonyl)adenine9-(2-hydroxy-3-nonyl)adenine: specific inhibitor of adenosine deaminase
coformycincoformycinsEC 3.5.4.4 (adenosine deaminase) inhibitor
adenosinequinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlitadenosines;
purines D-ribonucleoside
analgesic;
anti-arrhythmia drug;
fundamental metabolite;
human metabolite;
vasodilator agent
bergeninbergenin: RN refers to (2R-(2alpha,3beta,4alpha,4aalpha,10bbeta))-isomer; structuretrihydroxybenzoic acidmetabolite
nebularinenebularine : A purine ribonucleoside that is 9H-purine attached to a beta-D-ribofuranosyl residue at position 9 via a glycosidic (N-glycosyl) linkage.

nebularine: structure
purine ribonucleoside;
purines D-ribonucleoside
fungal metabolite
9-(2-hydroxy-3-nonyl)adenine(2R,3S)-EHNA : EHNA of absolute configuration 2R,3S. Selective inhibitor of cGMP-stimulated phosphodiesterase (PDE2) (IC50 = 0.8 - 4 mM). Also a potent inhibitor of adenosine deaminase.EHNAEC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
EC 3.5.4.4 (adenosine deaminase) inhibitor
9-(2-hydroxy-3-nonyl)adenine(2S,3R)-EHNA : EHNA of absolute configuration 2S,3R.EHNA
1-deazaadenosine1-deazaadenosine: inhibits nucleic acid & protein synthesis; structure given in first source
pentostatinpentostatin : A member of the class of coformycins that is coformycin in which the hydroxy group at position 2' is replaced with a hydrogen. It is a drug used for the treatment of hairy cell leukaemia.

Pentostatin: A potent inhibitor of ADENOSINE DEAMINASE. The drug induces APOPTOSIS of LYMPHOCYTES, and is used in the treatment of many lymphoproliferative malignancies, particularly HAIRY CELL LEUKEMIA. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity.
coformycinsantimetabolite;
antineoplastic agent;
Aspergillus metabolite;
bacterial metabolite;
EC 3.5.4.4 (adenosine deaminase) inhibitor
8-azanebularine8-azanebularine: structure in first source
msh, 4-nle-7-phe-alpha-polypeptidedermatologic drug
bi 653048 bs h3po4BI 653048 BS H3PO4: structure in first source